Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer

Area of Science:

• Oncology
• Medical Imaging
• Nanotechnology

Background:

• Sentinel lymph node (SLN) detection is crucial for staging breast and prostate cancers.
• Evidence for SLN detection using superparamagnetic iron oxide (SPIO) nanoparticles in vulvar cancer is limited.
• Standard SLN detection in vulvar cancer relies on technetium-99 radioisotope (Tc99).

Purpose of the Study:

• To compare the efficacy of SPIO nanoparticles versus Tc99 for SLN detection in vulvar cancer patients.
• To evaluate SPIO's performance as a tracer detected by a magnetometer against Tc99 detected by a gamma probe.
• To assess the non-inferiority of SPIO compared to the standard Tc99 procedure.

Main Methods:

• A prospective, single-center, interventional non-inferiority study.
• Compared SPIO tracer with Tc99 radioisotope in 18 vulvar cancer patients.
• Inclusion criteria aligned with the GROINSS-V study for selective SLN dissection.

Main Results:

• SPIO demonstrated non-inferiority to Tc99, with 92.7% agreement in SLN identification.
• SLN detection rates were 96.3% for Tc99 and 100% for SPIO per groin.
• Both SPIO and Tc99 achieved 100% detection rates for positive lymph nodes.

Conclusions:

• SPIO nanoparticles are a viable and non-inferior alternative for SLN detection in vulvar cancer.
• SPIO offers advantages including elimination of nuclear medicine requirements.
• Intraoperative injection of SPIO after anesthesia induction enhances procedural flexibility.